Market access for orphan drugs: Can your company break through in emerging markets?
Find out which emerging markets offer the best investment prospects for orphan drug manufacturers.
Get our new report, Orphan Drug Commercialisation and Market Access in Emerging Markets.
Based on interviews with eight senior executives and two specialist market access consultants, the report explores more than 35 emerging markets, and gives you a ranked list of the 15 most promising targets.
You'll understand emerging markets’ unique dynamics, hear about local stakeholders who help shape the market, and learn how to build the critical mass your product needs to win broad reimbursement at a fair price.
“There is a tendency in these markets to treat orphan drugs just like any other drug… The other element is a huge focus on price and cost”
– Ad Rietveld, Partner, RJW & Partners
The report is based on structured interviews with 10 subject matter experts: eight senior market access executives from leading orphan drug manufacturers, and two specialist market access consultants.
All respondents are responsible for their respective regions, or have special expertise in the countries surveyed, having led value dossier submissions and/or payer negotiations.
Interviews were conducted in April and May of 2016.
Need more information? Contact a consultant for an executive summary and sample pages from the report.
Market access for orphan drugs: Can your company break through in emerging markets?
Find out which emerging markets offer the best investment prospects for orphan drug manufacturers.
Get our new report, Orphan Drug Commercialisation and Market Access in Emerging Markets.
Based on interviews with eight senior executives and two specialist market access consultants, the report explores more than 35 emerging markets, and gives you a ranked list of the 15 most promising targets.
You'll understand emerging markets’ unique dynamics, hear about local stakeholders who help shape the market, and learn how to build the critical mass your product needs to win broad reimbursement at a fair price.
“There is a tendency in these markets to treat orphan drugs just like any other drug… The other element is a huge focus on price and cost”
– Ad Rietveld, Partner, RJW & Partners
The report is based on structured interviews with 10 subject matter experts: eight senior market access executives from leading orphan drug manufacturers, and two specialist market access consultants.
All respondents are responsible for their respective regions, or have special expertise in the countries surveyed, having led value dossier submissions and/or payer negotiations.
Interviews were conducted in April and May of 2016.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved